Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2017 Cantor Fitzgerald Global Healthcare Conference

Tuesday, September 19, 2017 8:15 PM UTC

ROCKVILLE, Md., Sept. 19, 2017 -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will webcast its corporate presentation at the 2017 Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26^th at 11:30AM Eastern.

Investors interested in arranging a meeting with the Company's management during this conference should contact the conference coordinator.

The presentation will be webcast live and may be accessed from the Event Calendar page of Sucampo's website at http://www.sucampo.com/investors/events-presentations/. A replay of the webcast will also be available on the Company's website for several days after the live event. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast.

About Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of highly specialized medicines. Sucampo has a late-stage pipeline of product candidates in clinical development for orphan disease areas, including VTS-270, a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1, a rare progressive genetic disorder. VTS-270 has also been granted breakthrough therapy designation in the U.S. Sucampo has an exclusive option for the North American rights to CPP-1X/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. The company has two marketed products – AMITIZA and RESCULA. For more information, please visit www.sucampo.com.

The Sucampo logo and the tagline, The Science of Innovation, are registered trademarks of Sucampo AG. AMITIZA is a registered trademark of Sucampo AG.

Contact:
Sucampo Pharmaceuticals, Inc.
Silvia Taylor
Senior Vice President, Investor Relations and Corporate Affairs
1-240-223-3718
[email protected]

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2017 Cantor Fitzgerald Global Healthcare Conference

Editor's Picks

Welcome to EconoTimes